Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immunicon IPO Proceeds To Support FDA Clearance Of Cancer Diagnostics

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson/Veridex will stand to benefit from Immunicon's proposed $70.9 mil. IPO under the terms of the companies' exclusive development, licensing and marketing agreement for cancer diagnostics
Advertisement

Related Content

People In Brief
People In Brief
Metastatic Breast Cancer Therapy Effectiveness Gauged By Immunicon Kits
Metastatic Breast Cancer Therapy Effectiveness Gauged By Immunicon Kits
J&J/Veridex’ CellSearch System Paves Way For FDA Class II Designation
J&J/Veridex’ CellSearch System Paves Way For FDA Class II Designation
Advertisement
UsernamePublicRestriction

Register

MT019978

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel